In April 2026, ZIVO signed a commercial-scale manufacturing agreement with Cyanotech Corporation to grow, cultivate and process Zivolife™ proprietary algal biomass at a 96-acre NELHA facility with year-round cycles and GRAS-certified operations. The company began trading on the OTCID marketplace in May 2026, reflecting a transition to streamlined reporting as it advances toward commercialization.
Cyborg Score Rationale
Zivo remains a pre-revenue or minimal-revenue biotech at an early commercialization stage with trailing twelve month revenue of $209K and negative EPS of -$2.18. While the manufacturing partnership with Cyanotech and ongoing animal health studies represent progress toward market traction, the company's microinvestor base (estimated ~7 employees), volatile stock price, and transition to OTC markets indicate significant execution risk.
Top Insights
(April 2026) Manufacturing agreement with Cyanotech provides commercial-scale production capacity for Zivolife™ algal biomass, positioning company for initial revenue generation
(June 2026) Transitioned to OTCID marketplace (May 2026) to reduce SEC compliance burden while pursuing animal health and human nutrition commercialization
Active development in poultry health applications, including USDA-funded avian influenza studies with University of Georgia targeting disease mitigation in broiler chickens
Minimal current revenue ($209K TTM) with negative profitability; company relies on capital markets and partnerships to fund R&D advancement
Named Competitors
Animal Health Division — Diversified agricultural and animal health supplier
Nutrition & Health Division — Global nutrition and health solutions provider
BPS Bioscience — Biotech research services and compounds
Bon Opus Biosciences — Life sciences research organization
Recent Developments
(May 2026) Transitioned common stock quotation to OTCID marketplace to streamline reporting and reduce compliance costs
(April 2026) Secured commercial-scale manufacturing agreement with Cyanotech Corporation for Zivolife™ algal biomass production
(December 2025) CFO resignation with interim successor appointed
(July 2025) Issued convertible debt offering for capital raise
Open the full interactive Zivo Bioscience, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.